17-7674225-C-T
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_000546.6(TP53):c.738G>A(p.Met246Ile) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,818 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000546.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 30
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461818Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 727220
GnomAD4 genome Cov.: 30
ClinVar
Submissions by phenotype
Li-Fraumeni syndrome Pathogenic:1
This sequence change replaces methionine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 246 of the TP53 protein (p.Met246Ile). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with TP53-related conditions. ClinVar contains an entry for this variant (Variation ID: 480961). Invitae Evidence Modeling incorporating data from in vitro experimental studies (PMID: 12826609, 29979965, 30224644) indicates that this missense variant is expected to disrupt TP53 function with a positive predictive value of 97.5%. Experimental studies have shown that this missense change affects TP53 function (PMID: 8336941, 10777217, 12826609, 22198284, 25881545, 26181206). For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.M246I variant (also known as c.738G>A), located in coding exon 6 of the TP53 gene, results from a G to A substitution at nucleotide position 738. The methionine at codon 246 is replaced by isoleucine, an amino acid with highly similar properties. This alteration has been identified in one individual meeting Chompret criteria (Ambry internal data). This variant is in the DNA binding domain of the TP53 protein and is reported to have loss of transactivation capacity and a dominant negative effect in yeast based assays (IARC TP53 database; Kato et al. Proc Natl Acad Sci USA. 2003 Jul 8;100(14):8424-9; Dearth LR et al. Carcinogenesis, 2007 Feb;28:289-98; Brachmann et al. Proc Natl Acad Sci USA. 1996 Apr 30;93(9):4091-5). Based on internal structural analysis, this variant is anticipated to result in a significant decrease in structural stability (Ambry internal data; Cho Y et al. Science 1994 Jul; 265(5170):346-55). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Hereditary breast ovarian cancer syndrome Pathogenic:1
. According to the ClinGen ACMG TP53 v1.4.0 criteria we chose these criteria: PS3 (strong pathogenic): Kato et al. 2003, LOF (PMID: 12826609); Dearth et al., 2007 DNE (PMID: 16861262), PM1 (medium pathogenic): ≥10 somatic observations cancerhotspots.org (v2), PM2 (supporting pathogenic): absent in gnomAD non-cancer v2/3 -
Neoplasm Other:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at